By the Top Tier Newswire AI Desk · September 11, 2026 at 10:38 AM ET · reviewed against 3 wire stories
AXSOME THERAPEUTICS (AXSM) is up +7.22% in the latest session. Our newswire has captured 3 stories on AXSM across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 54/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AXSM stock is up 7.22% at $226.35 as of the latest trade, driven by recent developments in the company’s clinical pipeline and renewed analyst optimism. The stock opened at $212.00 and reached an intraday high of $229.62 before settling near the upper end of its range. The move follows a presentation at the 12th Annual Cantor Fitzgerald Global Healthcare Conference and a series of analyst upgrades reinforcing long-term expectations.
What Happened
Axsome Therapeutics has been in the spotlight after dosing the first patient in its SUMMIT Phase 3 trial of AXS-05 for smoking cessation. This marks a key milestone for the company’s pipeline and signals progress in its efforts to expand the drug’s therapeutic applications. The presentation at the Cantor Fitzgerald conference, featuring company executive Mark Jacobson, likely increased visibility among institutional investors and analysts. Additionally, HC Wainwright & Co. and Mizuho have reiterated or raised their price targets, with the former maintaining a $290 target and the latter raising its target to $316. These developments have contributed to the stock’s upward momentum.
What The Data Shows
AXSM is currently trading near its 52-week high of $260.19, having printed one fresh 52-week low and eight fresh 52-week highs on September 11. The stock opened below its 52-week high but has since climbed into the upper half of its range. Intraday volume of 0.3 million shares is in line with the 3-month average. On the fundamentals, the company remains unprofitable with a trailing 12-month net margin of -24.7% and an EPS of -3.76, but revenue has grown 56.9% in the same period. Despite this, the stock has a market cap of $11.0 billion and a beta of 0.71, indicating relatively low volatility compared to the broader market.
What To Watch
The stock is currently in a strong position as it approaches its 52-week high. Investors may want to monitor the SUMMIT trial’s progress and any further analyst commentary. No earnings date is listed, but coverage breadth and price action could evolve quickly given the recent developments.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AXSM · Sep 11 session (5-min) · +4.56% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 3 stories · 54/100 neutral
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
1d agoThe Motley FoolNEUTRAL 53Analyst
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
2d agoSeeking AlphaBULLISH 56Product/PR
Axsome Therapeutics, Inc. (AXSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Axsome Therapeutics, Inc. (AXSM) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 2:45 PM EDTCompany ParticipantsMark Jacobson...
2d agoThe Motley FoolNEUTRAL 54Analyst
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →